EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial

NCT04891133 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

290

Enrollment

OTHER

Sponsor class

Stopped The trial was stopped prematurely due to external evidence that arose during the study period showing that the IMP, baricitinib, was not effective in the primary study population.

Conditions

COVID-19
Emerging Infectious Disease

Interventions

DRUG: Baricitinib
DRUG: Placebo

Sponsor

Oslo University Hospital

Collaborators

[object Object]
[object Object]